Navigation Links
Dragon Pharma announces 2007 full year financial results
Date:3/31/2008

continued to be the third largest producer and largest

exporter of 7-ACA and the dominating market leader of Clavulanic Acid

in China, with total sales volume of 568 tons for 7-ACA and 39 tons

for Clavulanic Acid.

- With a more focused antibiotic product portfolio and effective

marketing strategies, the Company has substantially expanded its

market share and realized an increase in sales quantity and sales

revenue of 128% and 156% respectively for its formulation drugs in

the Chinese market.

- Subsequent to the year end of 2007 and as previously announced, the

Company increased its annual production capacity for 7-ACA and

Clavulanic Acid by 30% and 56% respectively in order to meet rising

customer demand.

- Two new antibiotic products, Ceftazidime and Cefalexin, have been

successfully launched into the Chinese market.

Results for the Year Ended December 31, 2007

During 2007, the Company made a strategic decision to sell its EPO Division and fully focus on its chemical and formulation businesses that have shown significant growth since establishment in 2004. Dragon's efforts have successfully increased its sales, productions and profits for both the Chemical Division and Pharma Division. In the full year 2007, the total sale revenues reached $85.8 million, representing an increase of 63.7% from $52.4 million recorded for the full year 2006.

The Chemical Division continued to be the main growth driver and contributed 80% of the revenues for the Company in 2007. Under the favorable market conditions, the Company further increased its production level and achieved a utilization rate of 95% for 7-ACA production and 62% for Clavulanic Acid production. As the strong demand pushed up the market price for 7-ACA, the Company realized 568 tons of sales, an increase of 27% compared with 448 tons of sales for the same period of
'/>"/>

SOURCE Dragon Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dragon retains leading investor relations firm
2. Dragon announces new product launch; increase in annual production output capacity
3. Dragon Announces R&D Achievement in Biotech Manufacturing Process
4. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Transgenomic Opens Pharmacogenomics Laboratory in China
7. PharmAthene Reports Year-End 2007 Financial Results
8. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
9. China Pharma Holdings, Inc. Announces Record 2007 Year End Results
10. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
11. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... ... to market the TriPollar Technology- the most advanced 3rd generation Radio Frequency ... been clinically proven the world over to be safe and effective on ... enjoy visible results from the very 1st treatment. Long term results ...
... ... Ingelheim today announced results from the RE-COVER(TM) study investigating dabigatran etexilate ... warfarin in patients with acute VTE. Results of the trial ... and simultaneously published online in the New England Journal of ...
... , , Alberta Centre for Advanced ... & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ... like nanotechnology, biomaterials and microfluidics can play a powerful role ... health and improve the quality, cost and outcomes of patient ...
Cached Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... or persistent seizures into a medically induced coma currently ... monitor the patient,s brain activity and manually adjust drug ... Now a computer-controlled system developed by Massachusetts General Hospital ... more precise and efficient and opening the door to ...
... bad thing, but experiments by researcher Peter Chien and ... Amherst recently showed that for the bacteria Caulobacter ... is required to keep it alive. DNA ... processes in all organisms, says Chien, an assistant professor ...
... Mich. Researchers from the University of Michigan Comprehensive ... function of critical immune cell subsets called T-cells, which ... effect of lifesaving bone marrow transplants. These new ... T-cells help fight infections but also can trigger autoimmune ...
Cached Biology News:Automated system promises precise control of medically induced coma 2Automated system promises precise control of medically induced coma 3Biochemists find incomplete protein digestion is a useful thing for some bacteria 2Newly identified proteins make promising targets for blocking graft-vs.-host disease 2
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
... Bovine Calf Serum; U.S. ... seek an uncompromising quality; Low ... Collected from animals of US ... those who seek an uncompromising ...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
...
Biology Products: